Q32 Bio is a biotechnology company developing biologic therapeutics to restore healthy immune regulation. Focused on the IL-7 pathway and complement system, Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief. The company plans to commence a Phase 1 clinical trial evaluating its best-in-class IL-7R antibody ADX-914, a significant milestone marking Q32 Bio’s entry into clinical-stage development. Q32 Bio is located in the Boston area and is a spinout of CU Anschutz.